The board of directors Allergan plc (NYSE:AGN) on Thursday declared its dividend of USD0.72 per ordinary share for the second quarter of 2018.

This cash dividend is payable on 15 June 2018 to shareholders of record at the close of business as of 18 May 2018.

Headquartered in Dublin, Ireland, the pharmaceutical company is focused on developing, manufacturing and commercialising branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

In addition, the company markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology as well as anti-infective therapeutic categories.